Dry Eye Clinical Trial - Safety, Tolerability & Pharmacokinetics of 0.5% &

Status Completed

Clinical Trial Summary

The purpose of this two-part study is to evaluate safety, tolerability and pharmacokinetics of 0.5% and 2.5% cis-UCA eye drops in comparison to placebo in adult healthy volunteers.

Clinical Trial Description

This is a Phase I single-centre, double-blind, placebo-controlled, single and multiple dose study to evaluate safety, ocular tolerability and pharmacokinetics of 0.5% and 2.5% cis-UCA eye drops in healthy volunteers for up to 15 days. After the single day dose (three times) on day 1 and the subsequent 7 (± 1) days wash-out period, a multidose phase with three times a day administration for 14 days will start

Primary objectives:

- Part 1: To evaluate the safety and ocular tolerability of 0.5% and 2.5% cis-UCA eye drops and placebo for cis-UCA eye drops when administered on a randomized eye three times during a single day, assessed up to 7 (± 1) days following dosing in healthy volunteers

- Part 2: To evaluate the safety and ocular tolerability of 0.5% and 2.5% cis-UCA eye drops and placebo for cis-UCA eye drops when administered on both eyes three times a day for 14 days, assessed up to 7 days following the last dosing in healthy volunteers

Secondary objectives:

- To evaluate single dose pharmacokinetics of 0.5% and 2.5% cis-UCA eye drops when administered on a randomized eye in adult healthy volunteers

- To evaluate the pharmacokinetics of 0.5% and 2.5% cis-UCA eye drops when administered on both eyes three times a day for 14 days in adult healthy volunteers

Healthy male or female volunteer, 18-65 years of age, with no history of significant eye disease or any current eye disease that would affect the pharmacokinetics of cis-UCA. Subjects without any treatment-emergent adverse events during Part 1 may continue to Part 2 of the study. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Dry Eye

Clinical Trial Details

NCT number	NCT01476332
Study type	Interventional
Source	Laurantis Pharma, Ltd.
Contact
Status	Completed
Phase	Phase 1
Start date	November 2011
Completion date	March 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06159569` - Performance and Tolerability of the Medical Device LACRIACT	N/A
Completed	`NCT05102409` - An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease	Phase 2
Completed	`NCT05027087` - The Effect of a Novel Blueberry Supplement on Dry Eye Disease	Phase 3
Completed	`NCT04081610` - Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution	Phase 1
Completed	`NCT05062564` - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye	N/A
Completed	`NCT05825599` - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms	N/A
Completed	`NCT03418727` - Dry Eye Disease Study With Brimonidine	Phase 2
Active, not recruiting	`NCT04425551` - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction	N/A
Recruiting	`NCT04527887` - Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)	Phase 4
Not yet recruiting	`NCT06379685` - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.	Phase 1
Active, not recruiting	`NCT05618730` - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B	Phase 1
Completed	`NCT04553432` - Dry Eye OmniLenz Application of Omnigen Research Study	Phase 4
Recruiting	`NCT04109170` - Dry Eye Evaluation System Based on Bioinformatics
Completed	`NCT04105842` - Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type	N/A
Completed	`NCT05505292` - Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers	Phase 4
Completed	`NCT04668131` - Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease	N/A
Completed	`NCT06176651` - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers	Phase 4
Not yet recruiting	`NCT02218827` - Topical Steroid Treatment For Dry Eye	N/A
Completed	`NCT02235259` - Efficacy and Safety of XG-104 for the Treatment of Dry Eye	Phase 2
Completed	`NCT01959854` - Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Safety, Tolerability and Pharmacokinetics of 0.5% and 2.5% Cis-UCA Eye Drops in Adult Healthy Volunteers (Phase I)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms